What is Zacks Research’s Estimate for APVO Q2 Earnings?

Aptevo Therapeutics Inc. (NASDAQ:APVO) – Zacks Research issued their Q2 2026 earnings estimates for shares of Aptevo Therapeutics in a note issued to investors on Tuesday, June 16th. Zacks Research analyst D. Bautz anticipates that the biotechnology company will post earnings per share of ($5.83) for the quarter. The consensus estimate for Aptevo Therapeutics’ current full-year earnings is ($24.13) per share. Zacks Research also issued estimates for Aptevo Therapeutics’ Q3 2026 earnings at ($5.38) EPS, Q4 2026 earnings at ($5.14) EPS, FY2026 earnings at ($22.57) EPS, FY2027 earnings at ($2.78) EPS and FY2028 earnings at ($2.36) EPS.

APVO has been the topic of several other research reports. Weiss Ratings raised Aptevo Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a research note on Monday. Wall Street Zen raised Aptevo Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, March 29th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold”.

Aptevo Therapeutics Trading Down 2.7%

APVO opened at $4.67 on Friday. The stock has a market capitalization of $5.84 million, a P/E ratio of -0.02 and a beta of 1.68. Aptevo Therapeutics has a 12 month low of $3.80 and a 12 month high of $91.44. The firm’s fifty day simple moving average is $4.88 and its 200 day simple moving average is $8.06.

Aptevo Therapeutics (NASDAQ:APVO) last released its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported ($6.41) earnings per share for the quarter, meeting the consensus estimate of ($6.41).

Institutional Trading of Aptevo Therapeutics

An institutional investor recently bought a new stake in Aptevo Therapeutics stock. Virtu Financial LLC purchased a new stake in shares of Aptevo Therapeutics Inc. (NASDAQ:APVO) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 38,282 shares of the biotechnology company’s stock, valued at approximately $56,000. Virtu Financial LLC owned about 1.16% of Aptevo Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 8.06% of the stock is currently owned by hedge funds and other institutional investors.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Seattle, Washington, focused on the discovery and development of novel immunotherapies for oncology and autoimmune diseases. Founded in 2012 as a spin-off from Emergent BioSolutions, the company builds on expertise in protein engineering and translational research to create targeted biologics that engage the body’s immune system.

The company’s core technologies include the ADAPTIR platform, which enables the design of bispecific and multispecific protein scaffolds with customizable binding domains, and the KNOCKOUT platform, which incorporates non-natural amino acids to enhance therapeutic properties such as stability and half-life.